Condition: Advanced Gastrointestinal (GI) Malignancies · Hepatocellular Carcinoma · Gastric Cancer · Sponsor: Polaris Group
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| California Pacific Medical Center | San Francisco, California, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| The University of Chicago Medical Center | Chicago, Illinois, United States | — |
| The University of Kansas Cancer Center | Westwood, Kansas, United States | — |
| Masonic Cancer Center | Minneapolis, Minnesota, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | — |
| Oregon Health and Science University | Portland, Oregon, United States | — |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| University of Washington | Seattle, Washington, United States | — |
| The Chinese People's Liberation Army 81 Hospital | Nanjing, Jiangsu, China | — |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | — |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02102022